Form 4: Bruce Sachs Reports Acquisition of Vertex Pharmaceuticals Deferred Stock Units

Director Bruce Sachs acquired deferred stock units convertible to 90.32 shares of Vertex Pharmaceuticals common stock.

Summary

• On October 15, 2024, Bruce Sachs, a director of Vertex Pharmaceuticals, acquired deferred stock units representing the right to receive 90.32 shares of common stock.
• The price of the deferred stock units was $484.39.
• Following the transaction, Mr. Sachs directly owns 15,033.332 shares of Vertex Pharmaceuticals common stock.
• The deferred stock units are payable in common stock upon the earliest of Mr. Sachs' termination of service on the board, a change of control of Vertex Pharmaceuticals, or Mr. Sachs' disability or death.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing regarding stock ownership, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure of a director's acquisition of company stock, which is common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows confidence from a director in the company's future.

Key Dates